Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Kissei Adopts Iktos’ AI-Powered Drug Discovery System
July 4, 2023
- Maruho, Tsukuba Startup Ink ALDH2 Activator Deal
July 4, 2023
- 32 Pharma Execs Take Home Over 100 Million Yen in FY2022, Top 3 from Takeda: Securities Reports
July 3, 2023
- Meiji Seeks Booster Nod for COVID-19 mRNA Vaccine in Japan
July 3, 2023
- AstraZeneca Exits PhRMA in Japan after Global Decision
July 3, 2023
- Eisai Transfers Economic Rights for Breast Cancer Med to DRI
July 3, 2023
- Takeda Files Acquired Hemophilia A Therapy in Japan
July 3, 2023
- Shionogi’s Mulpleta Approved in China
July 3, 2023
- Taisho Launches 2nd Voluntary Redundancy Program
June 30, 2023
- Pfizer Japan Files BCMA Bispecific Elranatamab for MM
June 30, 2023
- CAR-T Player Noile-Immune Goes Public on TSE
June 30, 2023
- Shionogi Launches PIII Pediatric Study for Xocova in Japan
June 30, 2023
- Takeda CEO Touts Aggressive Dividend Policy as Deleveraging Drive Hits Goal
June 29, 2023
- Chugai Trims 150 Reps via Voluntary Buyout, Sales Force Down to 1,050 from July
June 29, 2023
- Astellas’ Hot Flash Med Nets Positive PIIIb Results in Europe
June 29, 2023
- Takeda CEO Earns 1.72 Billion Yen in FY2022, Down 135 Million Yen
June 29, 2023
- Keytruda Label Updated to Add Hodgkin Lymphoma Data
June 28, 2023
- UN-Backed Agency, 7 Firms Ink Deals for Generic Supply of Shionogi’s COVID Pill to LMICs
June 28, 2023
- Taiho, Kyushu University in Research Tie-Up on Covalent Reactive Groups
June 28, 2023
- Meiji Seika Pharma Files GVHD Drug Belumosudil in Japan
June 28, 2023
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…